Bridge Biotherapeutics is off to a great start with its recent successful Series A funding, raising the largest amount so far for a South Korean bioventure. The company’s CEO talks to Scrip about where the company is heading including plans for its first-in-class inflammatory bowel disease candidate and further financings.
A recent Series A funding will provide sufficient capital for Bridge Biotherapeutics to proceed with the global clinical development of its R&D pipeline until it launches a planned initial public offering in the next few years, says the CEO of the South Korean bioventure.
“If the [clinical] trials are successful, we won’t need further financing until we launch an IPO in the Kosdaq market...
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
Oral RNA splicing modulator has gone into a Phase II/III trial
